Low-dose sodium-glucose cotransporter 2 inhibitor ameliorates ischemic brain injury in mice through pericyte protection without glucose-lowering effects

Masamitsu Takashima; Kuniyuki Nakamura; Takuya Kiyohara; Yoshinobu Wakisaka; Masaoki Hidaka; Hayato Takaki; Kei Yamanaka; Tomoya Shibahara; Masanori Wakisaka; Tetsuro Ago; Takanari Kitazono

doi:10.1038/s42003-022-03605-4

Communications Biology (Jul 2022)

Low-dose sodium-glucose cotransporter 2 inhibitor ameliorates ischemic brain injury in mice through pericyte protection without glucose-lowering effects

Masamitsu Takashima,
Kuniyuki Nakamura,
Takuya Kiyohara,
Yoshinobu Wakisaka,
Masaoki Hidaka,
Hayato Takaki,
Kei Yamanaka,
Tomoya Shibahara,
Masanori Wakisaka,
Tetsuro Ago,
Takanari Kitazono

Affiliations

Masamitsu Takashima: Department of Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu University
Kuniyuki Nakamura: Department of Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu University
Takuya Kiyohara: Department of Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu University
Yoshinobu Wakisaka: Department of Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu University
Masaoki Hidaka: Department of Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu University
Hayato Takaki: Department of Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu University
Kei Yamanaka: Department of Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu University
Tomoya Shibahara: Department of Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu University
Masanori Wakisaka: Wakisaka Internal Medicine Clinic
Tetsuro Ago: Department of Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu University
Takanari Kitazono: Department of Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu University

DOI: https://doi.org/10.1038/s42003-022-03605-4
Journal volume & issue: Vol. 5, no. 1
pp. 1 – 11

Abstract

Read online

Pre-treatment of non-diabetic mice with the SGLT2 inhibitor, luseogliflozin, reduces brain damage and neurological dysfunction following middle cerebral artery occlusion by acquiring ischemic tolerance in pericytes.

Published in Communications Biology

ISSN: 2399-3642 (Online)
Publisher: Nature Portfolio
Country of publisher: United Kingdom
LCC subjects: Science: Biology (General)
Website: https://www.nature.com/commsbio/

About the journal